MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412908 | Name: Cinacalcet (m2a-glu)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cinacalcet (m2a-glu) is a calcium reducer that can lower the amount of calcium in the blood.

Chemical Structure

Cinacalcet (m2a-glu)
Cinacalcet (m2a-glu)
CAS#848608-66-2

Theoretical Analysis

MedKoo Cat#: 412908

Name: Cinacalcet (m2a-glu)

CAS#: 848608-66-2

Chemical Formula: C28H32F3NO8

Exact Mass: 567.2080

Molecular Weight: 567.56

Elemental Analysis: C, 59.26; H, 5.68; F, 10.04; N, 2.47; O, 22.55

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Cinacalcet (m2a-glu); UNII-58WPD2QM9Y
IUPAC/Chemical Name
1,2-Dihydro-2-hydroxy-4-((1R)-1-((3-(3-(trifluoromethyl)phenyl)propyl)amino)ethyl)-1-naphthalenyl-beta-D-glucopyranosiduronic acid, (1R,2R)-
InChi Key
SUGWRQLAHMJIFZ-WQDVSFBUSA-N
InChi Code
InChI=1S/C28H32F3NO8/c1-14(32-11-5-7-15-6-4-8-16(12-15)28(29,30)31)19-13-20(33)24(18-10-3-2-9-17(18)19)39-27-23(36)21(34)22(35)25(40-27)26(37)38/h2-4,6,8-10,12-14,20-25,27,32-36H,5,7,11H2,1H3,(H,37,38)/t14-,20-,21+,22+,23-,24-,25+,27-/m1/s1
SMILES Code
O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1O[C@H]2[C@H](O)C=C([C@H](NCCCC3=CC=CC(C(F)(F)F)=C3)C)C4=C2C=CC=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 567.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Eidman KE, Wetmore JB. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? Semin Dial. 2018 Sep;31(5):440-444. doi: 10.1111/sdi.12734. Epub 2018 Jul 15. PMID: 30009474. 2: Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468. PMID: 28097356. 3: Susantitaphong P, Vadcharavivad S, Susomboon T, Singhan W, Dumrongpisutikul N, Jakchairoongruang K, Eiam-Ong S, Praditpornsilpa K. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail. 2019 Nov;41(1):326-333. doi: 10.1080/0886022X.2018.1562356. PMID: 31014177; PMCID: PMC6493313. 4: Joseph C, Shah S, Geer J, Juarez-Calderon M, Srivaths PR, Swartz SJ. Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years. Clin Nephrol. 2019 Dec;92(6):279-286. doi: 10.5414/CN109871. PMID: 31587754. 5: Mostafa GAE, Al-Badr AA. Cinacalcet Hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2017;42:1-90. doi: 10.1016/bs.podrm.2017.02.001. Epub 2017 Apr 3. PMID: 28431775. 6: Sekercioglu N, Busse JW, Sekercioglu MF, Agarwal A, Shaikh S, Lopes LC, Mustafa RA, Guyatt GH, Thabane L. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2016 Jul;38(6):857-74. doi: 10.3109/0886022X.2016.1172468. Epub 2016 May 2. PMID: 27137817. 7: Dulfer RR, Koh EY, van der Plas WY, Engelsman AF, van Dijkum EJMN, Pol RA, Vogt L, de Borst MH, Kruijff S, Schepers A, Appelman-Dijkstra NM, Rotmans JI, Hesselink DA, van Eijck CHJ, Hoorn EJ, van Ginhoven TM; Dutch Hyperparathyroid Study Group. Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis. Langenbecks Arch Surg. 2019 Feb;404(1):71-79. doi: 10.1007/s00423-019-01755-4. Epub 2019 Feb 7. PMID: 30729318; PMCID: PMC6394681. 8: Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, Brøndum Frøkjær J, Vestergaard P. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020 May;8(5):407-417. doi: 10.1016/S2213-8587(20)30063-2. PMID: 32333877. 9: Cruzado JM, Moreno P, Torregrosa JV, Taco O, Mast R, Gómez-Vaquero C, Polo C, Revuelta I, Francos J, Torras J, García-Barrasa A, Bestard O, Grinyó JM. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism. J Am Soc Nephrol. 2016 Aug;27(8):2487-94. doi: 10.1681/ASN.2015060622. Epub 2015 Dec 8. PMID: 26647424; PMCID: PMC4978046. 10: Manaka K, Sato J, Kinoshita Y, Ito N, Fujita M, Iiri T, Nangaku M, Makita N. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. Endocr J. 2019 Aug 29;66(8):683-689. doi: 10.1507/endocrj.EJ19-0034. Epub 2019 May 16. PMID: 31092749.